TP53 and leukemia: To assess if FLT3 status contributes to their sensitivity to the DNR/M3814 combination, we extended the p53 wild-type cancer cell panel with two FLT3 wild-type/p53 wild-type leukemia cell lines, ML-2 and M-07e.